Physician profile
Dewey Le
NPI 1447454012
$1,532.66
in general payments reported to CMS, 2019-2025
25 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $109 · 2021: $234 · 2022: $144 · 2023: $426 · 2024: $139 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $199.20 | 2025 | Gore Cardioform Septal Occluder |
| Novartis Pharmaceuticals Corporation | $191.43 | 2019-2023 | |
| Abbvie INC. | $166.07 | 2021-2025 | |
| Lilly USA, LLC | $119.33 | 2019-2023 | Emgality, Reyvow, Amyvid |
| Lundbeck LLC | $109.52 | 2022-2024 | Rexulti, Vyepti |
| Biogen, INC. | $83.91 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $82.26 | 2019-2023 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $80.08 | 2022-2024 | Ingrezza, Ongentys |
| Merz Pharmaceuticals, LLC | $61.70 | 2021 | |
| Amneal Pharmaceuticals LLC | $52.98 | 2022-2024 | Rytary |
| Livanova USA, INC. | $50.94 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceuticals, INC. | $46.69 | 2021 | |
| Pfizer INC. | $42.29 | 2024 | |
| Medtronic USA, INC. | $36.11 | 2019 | |
| Sk Life Science, INC. | $30.00 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.52 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $23.47 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $20.60 | 2023 | Rexulti |
| Genzyme Corporation | $20.02 | 2020 | |
| Argenx US, INC. | $19.21 | 2023 | Vyvgart Hytrulo |
| Ucb, INC. | $17.54 | 2019 | |
| Insightec,INC | $15.93 | 2023 | Exablate |
| Promius Pharma LLC | $13.43 | 2019 | |
| Celgene Corporation | $12.56 | 2021 | |
| Emd Serono, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dewey Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.